Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

13.25 -0.17 (-1.27%)
Streaming Delayed Price Updated: 11:24 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today? ↗
Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. 
Via InvestorPlace
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
Via Benzinga
News headline image
What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today ↗
Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM... 
Via Benzinga
News headline image
Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat ↗
Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO... 
Via Benzinga
News headline image
Chinese Stocks Are Falling: What's Going On? ↗
Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as... 
Via Benzinga
News headline image
Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble ↗
The SEC is calling out a several stocks for non-compliance. Could they face delisting? 
Via Investor's Business Daily
News headline image
Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition ↗
Hutchmed (China) Limited (NASDAQ: HCM) reported FY21 sales of $356.1 million, up 56% Y/Y, driven by commercial progress on three in-house developed oncology drugs... 
Via Benzinga
News headline image
Earnings Scheduled For March 3, 2022 ↗
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
News headline image
Week In Review: Biopharma Deals Slow During Chinese New Year Week ↗
Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine... 
Via Talk Markets
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
News headline image
31 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
News headline image
18 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO... 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
Via Benzinga
News headline image
40 Stocks Moving In Monday's Mid-Day Session ↗
Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking... 
Via Benzinga
News headline image
20 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per... 
Via Benzinga
News headline image
Week In Review: Broncus Stages $200 Million Hong Kong IPO For Pulmonary Devices ↗
Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. The IPO was priced at the top end of... 
Via Talk Markets
Topics Initial Public Offering
News headline image
HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China ↗
The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited... 
Via Benzinga
News headline image
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal ↗
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
News headline image
Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China ↗
Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (... 
Via Benzinga
News headline image
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
From Epizyme, Inc.
Via Business Wire
News headline image
Hutchison China MediTech Ltd (HCM) Q2 2021 Earnings Call Transcript ↗
HCM earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares moved upwards by 40.13% to $2.13 during Wednesday's pre-market session. The company's market cap stands at $... 
Via Benzinga
News headline image
62 Biggest Movers From Yesterday ↗
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to... 
Via Benzinga
Topics Cannabis
News headline image
Hutchmed Stock Gains On Kick Starting Mid-Stage Gastric Cancer Trial With AstraZeneca's Orpathys ↗
HUTCHMED (China) Limited (NASDAQ: HCM) and AstraZeneca Plc (NASDAQ: AZN) have initiated a Phase 2 study of Orpathys (savolitinib) in patients with... 
Via Benzinga
News headline image
50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares jumped 59.9% to $2.43. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the company highlighted the... 
Via Benzinga
News headline image
28 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares rose 38.2% to $2.10 in pre-market trading. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton... 
Via Benzinga
News headline image
Hutchmed's Stock Rises After EMA Validates Surufatinib Application For Neuroendocrine Tumors ↗
The European Medicines Agency (EMA) has validated and accepted Hutchmed (China) Limited's (NASDAQ: HCM) marketing application seeking approval for surufatinib... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.